Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), United Therapeutics (UTHR) and Alnylam Pharma (ALNY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), United Therapeutics (UTHR – Research Report) and Alnylam Pharma (ALNY – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sarepta Therapeutics (SRPT)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics yesterday and set a price target of $18.00. The company’s shares closed last Thursday at $17.28.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
Currently, the analyst consensus on Sarepta Therapeutics is a Hold with an average price target of $21.81, implying a 22.5% upside from current levels. In a report released yesterday, Goldman Sachs also maintained a Hold rating on the stock with a $17.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
United Therapeutics (UTHR)
Jefferies analyst Roger Song maintained a Buy rating on United Therapeutics today and set a price target of $640.00. The company’s shares closed last Thursday at $507.95.
According to TipRanks.com, Song is a 1-star analyst with an average return of
United Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $576.13, which is an 8.7% upside from current levels. In a report issued on February 17, UBS also maintained a Buy rating on the stock with a $645.00 price target.
Alnylam Pharma (ALNY)
In a report released yesterday, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma, with a price target of $510.00. The company’s shares closed last Thursday at $326.56.
According to TipRanks.com, Trucchio is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $455.84 average price target, implying a 38.7% upside from current levels. In a report issued on February 14, TipRanks – Google also upgraded the stock to Buy with a $349.00 price target.
